Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma
To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). Among 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predict...
Saved in:
| Published in | Gut and liver Vol. 11; no. 3; pp. 409 - 416 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Editorial Office of Gut and Liver
15.05.2017
Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1976-2283 2005-1212 2005-1212 |
| DOI | 10.5009/gnl16001 |
Cover
| Abstract | To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).
Among 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predictive factors for CR, recurrence after CR, and overall survival (OS).
Eighty-one patients (28.2%) achieved CR after TACE, and recurrence after CR was detected in 35 patients (43.2%). In multivariate analyses, tumor size (≤5 cm) and single nodularity were predictive factors for CR, with hazard ratios (HRs) of 0.35 (p=0.002) and 0.41 (p<0.001), respectively. Elevated serum α-fetoprotein (AFP) (>20 ng/mL) level and multinodularity exhibited significant relationships with recurrence after CR, with HRs of 2.220 (p=0.026) and 3.887 (p<0.001), respectively. Tumor size (>5 cm), multinodularity, elevated serum AFP (>20 ng/mL) level, Child-Turcotte-Pugh score (B and C), and portal vein thrombosis were significant factors for OS.
In patients treated with TACE as a first therapy, tumor size (≤5 cm) and single nodularity were predictive factors for CR, and multinodularity and elevated serum AFP (>20 ng/mL) levels were predictive factors for recurrence after CR. These factors were also significant for OS. |
|---|---|
| AbstractList | Background/AimsTo investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).Methods : Among 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predictive factors for CR, recurrence after CR, and overall survival (OS).Results : Eighty-one patients (28.2%) achieved CR after TACE, and recurrence after CR was detected in 35 patients (43.2%). In multivariate analyses, tumor size (≤5 cm) and single nodularity were predictive factors for CR, with hazard ratios (HRs) of 0.35 (p=0.002) and 0.41 (p<0.001), respectively. Elevated serum α-fetoprotein (AFP) (>20 ng/mL) level and multinodularity exhibited significant relationships with recurrence after CR, with HRs of 2.220 (p=0.026) and 3.887 (p<0.001), respectively. Tumor size (>5 cm), multinodularity, elevated serum AFP (>20 ng/mL) level, Child-Turcotte-Pugh score (B and C), and portal vein thrombosis were significant factors for OS.Conclusion : sIn patients treated with TACE as a first therapy, tumor size (≤5 cm) and single nodularity were predictive factors for CR, and multinodularity and elevated serum AFP (>20 ng/mL) levels were predictive factors for recurrence after CR. These factors were also significant for OS. To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). Among 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predictive factors for CR, recurrence after CR, and overall survival (OS). Eighty-one patients (28.2%) achieved CR after TACE, and recurrence after CR was detected in 35 patients (43.2%). In multivariate analyses, tumor size (≤5 cm) and single nodularity were predictive factors for CR, with hazard ratios (HRs) of 0.35 (p=0.002) and 0.41 (p<0.001), respectively. Elevated serum α-fetoprotein (AFP) (>20 ng/mL) level and multinodularity exhibited significant relationships with recurrence after CR, with HRs of 2.220 (p=0.026) and 3.887 (p<0.001), respectively. Tumor size (>5 cm), multinodularity, elevated serum AFP (>20 ng/mL) level, Child-Turcotte-Pugh score (B and C), and portal vein thrombosis were significant factors for OS. In patients treated with TACE as a first therapy, tumor size (≤5 cm) and single nodularity were predictive factors for CR, and multinodularity and elevated serum AFP (>20 ng/mL) levels were predictive factors for recurrence after CR. These factors were also significant for OS. To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).BACKGROUND/AIMSTo investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).Among 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predictive factors for CR, recurrence after CR, and overall survival (OS).METHODSAmong 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predictive factors for CR, recurrence after CR, and overall survival (OS).Eighty-one patients (28.2%) achieved CR after TACE, and recurrence after CR was detected in 35 patients (43.2%). In multivariate analyses, tumor size (≤5 cm) and single nodularity were predictive factors for CR, with hazard ratios (HRs) of 0.35 (p=0.002) and 0.41 (p<0.001), respectively. Elevated serum α-fetoprotein (AFP) (>20 ng/mL) level and multinodularity exhibited significant relationships with recurrence after CR, with HRs of 2.220 (p=0.026) and 3.887 (p<0.001), respectively. Tumor size (>5 cm), multinodularity, elevated serum AFP (>20 ng/mL) level, Child-Turcotte-Pugh score (B and C), and portal vein thrombosis were significant factors for OS.RESULTSEighty-one patients (28.2%) achieved CR after TACE, and recurrence after CR was detected in 35 patients (43.2%). In multivariate analyses, tumor size (≤5 cm) and single nodularity were predictive factors for CR, with hazard ratios (HRs) of 0.35 (p=0.002) and 0.41 (p<0.001), respectively. Elevated serum α-fetoprotein (AFP) (>20 ng/mL) level and multinodularity exhibited significant relationships with recurrence after CR, with HRs of 2.220 (p=0.026) and 3.887 (p<0.001), respectively. Tumor size (>5 cm), multinodularity, elevated serum AFP (>20 ng/mL) level, Child-Turcotte-Pugh score (B and C), and portal vein thrombosis were significant factors for OS.In patients treated with TACE as a first therapy, tumor size (≤5 cm) and single nodularity were predictive factors for CR, and multinodularity and elevated serum AFP (>20 ng/mL) levels were predictive factors for recurrence after CR. These factors were also significant for OS.CONCLUSIONSIn patients treated with TACE as a first therapy, tumor size (≤5 cm) and single nodularity were predictive factors for CR, and multinodularity and elevated serum AFP (>20 ng/mL) levels were predictive factors for recurrence after CR. These factors were also significant for OS. Background/Aims: To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). Methods: Among 691 newly diagnosed HCC patients, 287 were treated with TACE as a first therapy. We analyzed the predictive factors for CR, recurrence after CR, and overall survival (OS). Results: Eighty-one patients (28.2%) achieved CR after TACE, and recurrence after CR was detected in 35 patients (43.2%). In multivariate analyses, tumor size (≤5 cm) and single nodularity were predictive factors for CR, with hazard ratios (HRs) of 0.35 (p=0.002) and 0.41 (p<0.001), respectively. Elevated serum α-fetoprotein (AFP) (>20 ng/mL) level and multinodularity exhibited significant relationships with recurrence after CR, with HRs of 2.220 (p=0.026) and 3.887 (p<0.001), respectively. Tumor size (>5 cm), multinodularity, elevated serum AFP (>20 ng/mL) level, Child-Turcotte-Pugh score (B and C), and portal vein thrombosis were significant factors for OS. Conclusions: In patients treated with TACE as a first therapy, tumor size (≤5 cm) and single nodularity were predictive factors for CR, and multinodularity and elevated serum AFP (>20 ng/mL) levels were predictive factors for recurrence after CR. These factors were also significant for OS. KCI Citation Count: 13 |
| Author | Kim, Sang Gyune Jeong, Soung Won Jeong, Shin Ok Cho, Young Deok Lee, Sae Hwan Park, Su Yeon Kim, Eui Bae Kim, Hong Soo Goo, Dong Erk Cha, Sang Woo Kim, Young Seok Kim, Yong Jae Jang, Jae Young Kim, Boo Sung |
| AuthorAffiliation | 4 Department of Radiology, Soonchunhyang University Hospital, Seoul, Korea 2 Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan, Korea 5 Department of Biostatistics, Soonchunhyang University Hospital, Seoul, Korea 3 Department of Internal Medicine, Soonchunhyang University Hospital, Bucheon, Korea 1 Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea |
| AuthorAffiliation_xml | – name: 2 Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan, Korea – name: 5 Department of Biostatistics, Soonchunhyang University Hospital, Seoul, Korea – name: 4 Department of Radiology, Soonchunhyang University Hospital, Seoul, Korea – name: 1 Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea – name: 3 Department of Internal Medicine, Soonchunhyang University Hospital, Bucheon, Korea |
| Author_xml | – sequence: 1 givenname: Shin Ok surname: Jeong fullname: Jeong, Shin Ok organization: Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul – sequence: 2 givenname: Eui Bae surname: Kim fullname: Kim, Eui Bae organization: Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul – sequence: 3 givenname: Soung Won surname: Jeong fullname: Jeong, Soung Won organization: Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul – sequence: 4 givenname: Jae Young surname: Jang fullname: Jang, Jae Young organization: Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul – sequence: 5 givenname: Sae Hwan surname: Lee fullname: Lee, Sae Hwan organization: Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan – sequence: 6 givenname: Sang Gyune surname: Kim fullname: Kim, Sang Gyune organization: Department of Internal Medicine, Soonchunhyang University Hospital, Bucheon – sequence: 7 givenname: Sang Woo surname: Cha fullname: Cha, Sang Woo organization: Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul – sequence: 8 givenname: Young Seok surname: Kim fullname: Kim, Young Seok organization: Department of Internal Medicine, Soonchunhyang University Hospital, Bucheon – sequence: 9 givenname: Young Deok surname: Cho fullname: Cho, Young Deok organization: Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul – sequence: 10 givenname: Hong Soo surname: Kim fullname: Kim, Hong Soo organization: Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan – sequence: 11 givenname: Boo Sung surname: Kim fullname: Kim, Boo Sung organization: Institute for Digestive Research and Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul – sequence: 12 givenname: Yong Jae surname: Kim fullname: Kim, Yong Jae organization: Department of Radiology, Soonchunhyang University Hospital, Seoul, Korea – sequence: 13 givenname: Dong Erk surname: Goo fullname: Goo, Dong Erk organization: Department of Radiology, Soonchunhyang University Hospital, Seoul, Korea – sequence: 14 givenname: Su Yeon surname: Park fullname: Park, Su Yeon organization: Department of Biostatistics, Soonchunhyang University Hospital, Seoul, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28208001$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002224193$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNplkk1v2zAMhoWhw5p2A_YLBh-3Qzp92LJ8GVAE_QhQYEORnQWZplO1spRJdoHu11dJ2m7dThSllw8pkkfkwAePhHxk9KSitPm69o5JStkbMuOUVnPGGT8gM9bUcs65EofkKKVbSiXjdfWOHHLFqcr6GXn4EbGzMNp7LM4NjCGmog-xWIRh43DE4hrTJviEhfFddmCKET1ktx8xFqtofDIxH61xxeIGh4BDG5z9bUYbfGF9cYkbMwZA5yZnMthEsD4M5j152xuX8MOTPSY_z89Wi8v51feL5eL0ag6VUONcKllWICouqAJBjeRQdVK0osTKdG1tJLZ9LVnflUI2si4BWyGE6g2UrGFMHJMve66Pvb4Dq4OxO7sO-i7q0-vVUjNRCya32uVe2wVzqzfRDiY-7AJ2FyGudf6sBYe6ykVh7jVloEooocWGcVCIANIIBpn1bc_aTO2AHaAfo3GvoK9fvL3JNd3rqmR1rcoM-PwEiOHXhGnUg03bPhqPYUqaKdk0UjVUZOmnv3O9JHme8x8WxJBSxP5FwqjerpB-XqEsPflHCnbcTTNXad3_AY9sDMo8 |
| CitedBy_id | crossref_primary_10_22575_interventionalradiology_2020_0025 crossref_primary_10_2957_kanzo_62_456 crossref_primary_10_1016_j_transproceed_2024_08_033 crossref_primary_10_1016_j_acra_2021_10_012 crossref_primary_10_3390_diagnostics12030665 crossref_primary_10_1016_j_jvir_2019_07_029 crossref_primary_10_1080_17474124_2020_1823215 crossref_primary_10_3748_wjg_v29_i15_2261 crossref_primary_10_1002_jmri_26977 crossref_primary_10_3389_fmolb_2021_634606 crossref_primary_10_1007_s00330_021_07910_0 crossref_primary_10_1590_1414_431x2024e13661 crossref_primary_10_1371_journal_pone_0206381 crossref_primary_10_4143_crt_2019_533 crossref_primary_10_3390_cancers15204991 crossref_primary_10_18632_oncotarget_22123 crossref_primary_10_32322_jhsm_1118649 crossref_primary_10_1159_000487311 crossref_primary_10_1007_s12664_021_01227_y crossref_primary_10_3892_ol_2017_6489 crossref_primary_10_1186_s43066_021_00155_y crossref_primary_10_1016_j_crad_2024_01_014 crossref_primary_10_1148_ryai_2019180021 crossref_primary_10_1007_s00261_023_03868_3 crossref_primary_10_1159_000530441 crossref_primary_10_1186_s43055_024_01187_1 crossref_primary_10_1016_j_crad_2019_07_023 crossref_primary_10_3390_diagnostics12061308 crossref_primary_10_1097_JS9_0000000000000942 crossref_primary_10_12688_f1000research_134088_1 crossref_primary_10_1097_MEG_0000000000002442 crossref_primary_10_1097_HC9_0000000000000466 crossref_primary_10_1007_s12029_021_00743_6 crossref_primary_10_1038_s41598_021_01839_6 crossref_primary_10_1097_MD_0000000000026584 crossref_primary_10_1016_j_diii_2022_01_006 crossref_primary_10_1111_apt_14823 crossref_primary_10_2147_JHC_S316117 crossref_primary_10_1038_s41597_023_01928_3 crossref_primary_10_1007_s00261_020_02701_5 crossref_primary_10_1007_s00262_021_03087_z crossref_primary_10_3389_fonc_2022_809860 crossref_primary_10_1007_s00270_019_02365_9 crossref_primary_10_3390_curroncol28010095 crossref_primary_10_3389_fonc_2022_819934 crossref_primary_10_1007_s00261_021_02992_2 crossref_primary_10_1007_s00261_023_04117_3 crossref_primary_10_1111_1754_9485_12948 crossref_primary_10_1186_s12885_023_11491_0 |
| Cites_doi | 10.1002/hep.21408 10.1097/CJI.0b013e31802fd8e2 10.1053/j.gastro.2006.05.021 10.1007/s005340200058 10.3748/wjg.v20.i22.6995 10.1002/cncr.11111 10.1053/j.gastro.2008.02.090 10.1016/j.critrevonc.2006.06.001 10.1111/j.1365-2036.2011.04694.x 10.1038/sj.bjc.6604282 10.1002/1097-0142(20010301)91:5<949::AID-CNCR1084>3.0.CO;2-H 10.1046/j.1440-1746.2001.02610.x 10.3748/wjg.v11.i36.5601 10.1016/j.ejrad.2010.12.058 10.1371/journal.pone.0032653 10.1200/JCO.2009.23.1282 10.1016/S0168-8278(02)00360-4 10.1007/BF03265492 10.1016/j.jvir.2012.12.013 10.1111/j.1749-6632.2002.tb04090.x 10.1007/s00330-005-0029-9 10.1111/hepr.12083 10.1055/s-0030-1247132 10.1002/hep.24199 10.1016/S1386-6346(02)00144-4 10.1002/ijc.25516 10.1007/s13277-011-0237-7 10.3350/cmh.2016.22.1.7 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. 2017 |
| Copyright_xml | – notice: Copyright © 2017 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA ACYCR |
| DOI | 10.5009/gnl16001 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2005-1212 |
| EndPage | 416 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_1373161 oai_doaj_org_article_55c3e00501c84c4cbe912c8eecc6a31c PMC5417784 28208001 10_5009_gnl16001 |
| Genre | Evaluation Study Journal Article |
| GroupedDBID | --- 5-W 8JR 9ZL AAKDD AAYXX ABDBF ACUHS ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. F5P GROUPED_DOAJ GX1 HYE HZB OK1 RPM CGR CUY CVF ECM EIF M~E NPM 7X8 5PM 53G 85H |
| ID | FETCH-LOGICAL-c538t-68645c352308c30a62c5d63b34e5adb7a6ebf761fd4369674ceb3338fac419113 |
| IEDL.DBID | DOA |
| ISSN | 1976-2283 2005-1212 |
| IngestDate | Tue Nov 21 21:46:56 EST 2023 Wed Aug 27 01:26:28 EDT 2025 Thu Aug 21 13:21:13 EDT 2025 Fri Jul 11 16:30:53 EDT 2025 Thu Jan 02 22:55:35 EST 2025 Tue Jul 01 00:42:49 EDT 2025 Thu Apr 24 23:10:27 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | therapeutic Recurrence Carcinoma Complete response Chemoembolization hepatocellular |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c538t-68645c352308c30a62c5d63b34e5adb7a6ebf761fd4369674ceb3338fac419113 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Shin Ok Jeong and Eui Bae Kim contributed equally to this work as first authors. |
| OpenAccessLink | https://doaj.org/article/55c3e00501c84c4cbe912c8eecc6a31c |
| PMID | 28208001 |
| PQID | 1869968903 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_1373161 doaj_primary_oai_doaj_org_article_55c3e00501c84c4cbe912c8eecc6a31c pubmedcentral_primary_oai_pubmedcentral_nih_gov_5417784 proquest_miscellaneous_1869968903 pubmed_primary_28208001 crossref_primary_10_5009_gnl16001 crossref_citationtrail_10_5009_gnl16001 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-May-15 |
| PublicationDateYYYYMMDD | 2017-05-15 |
| PublicationDate_xml | – month: 05 year: 2017 text: 2017-May-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Gut and liver |
| PublicationTitleAlternate | Gut Liver |
| PublicationYear | 2017 |
| Publisher | Editorial Office of Gut and Liver Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회 |
| Publisher_xml | – name: Editorial Office of Gut and Liver – name: Gastroenterology Council for Gut and Liver – name: 거트앤리버 소화기연관학회협의회 |
| References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – ident: ref5 – ident: ref13 doi: 10.1002/hep.21408 – ident: ref28 doi: 10.1097/CJI.0b013e31802fd8e2 – ident: ref10 doi: 10.1053/j.gastro.2006.05.021 – ident: ref18 doi: 10.1007/s005340200058 – ident: ref24 doi: 10.3748/wjg.v20.i22.6995 – ident: ref22 doi: 10.1002/cncr.11111 – ident: ref6 doi: 10.1053/j.gastro.2008.02.090 – ident: ref7 doi: 10.1016/j.critrevonc.2006.06.001 – ident: ref11 doi: 10.1111/j.1365-2036.2011.04694.x – ident: ref16 doi: 10.1038/sj.bjc.6604282 – ident: ref14 doi: 10.1002/1097-0142(20010301)91:5<949::AID-CNCR1084>3.0.CO;2-H – ident: ref25 doi: 10.1046/j.1440-1746.2001.02610.x – ident: ref17 doi: 10.3748/wjg.v11.i36.5601 – ident: ref12 doi: 10.1016/j.ejrad.2010.12.058 – ident: ref3 doi: 10.1371/journal.pone.0032653 – ident: ref27 doi: 10.1200/JCO.2009.23.1282 – ident: ref15 doi: 10.1016/S0168-8278(02)00360-4 – ident: ref29 doi: 10.1007/BF03265492 – ident: ref23 doi: 10.1016/j.jvir.2012.12.013 – ident: ref2 doi: 10.1111/j.1749-6632.2002.tb04090.x – ident: ref26 doi: 10.1007/s00330-005-0029-9 – ident: ref4 doi: 10.1111/hepr.12083 – ident: ref21 doi: 10.1055/s-0030-1247132 – ident: ref19 doi: 10.1002/hep.24199 – ident: ref20 doi: 10.1016/S1386-6346(02)00144-4 – ident: ref1 doi: 10.1002/ijc.25516 – ident: ref9 doi: 10.1007/s13277-011-0237-7 – ident: ref8 doi: 10.3350/cmh.2016.22.1.7 |
| SSID | ssj0061275 |
| Score | 2.334609 |
| Snippet | To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated with... Background/AimsTo investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC) treated... Background/Aims: To investigate the predictive factors for complete response (CR) and recurrence after CR in patients with hepatocellular carcinoma (HCC)... |
| SourceID | nrf doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 409 |
| SubjectTerms | Aged alpha-Fetoproteins - analysis carcinoma Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - complications Carcinoma, Hepatocellular - therapy chemoembolization Chemoembolization, Therapeutic - methods complete response Female hepatocellular Humans Liver Neoplasms - blood Liver Neoplasms - complications Liver Neoplasms - therapy Male Middle Aged Neoplasm Recurrence, Local - etiology Original Proportional Hazards Models recurrence Retrospective Studies Risk Factors Severity of Illness Index therapeutic Treatment Outcome Venous Thrombosis - etiology 내과학 |
| Title | Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28208001 https://www.proquest.com/docview/1869968903 https://pubmed.ncbi.nlm.nih.gov/PMC5417784 https://doaj.org/article/55c3e00501c84c4cbe912c8eecc6a31c https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002224193 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Gut and Liver, 2017, 11(3), , pp.409-416 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLafrcPoJaCj2ZWKuXfUxCl20hpZQGchPSWE6XbOSy3Rzy7zsjeZdsCPTSk18SHmtGmhl7_H2MfWy9BwMaKl-jBSvR9VUTWlUF1L7vRGv7_N_a6TczP1Nfz_X5Laovqgkr8MBl4A61BhkJpURAo0BBiK2YQhPx1sZLAbT61m29SabKGmwItjx_T7amIoCXAjurMaA4vEhLQV5-xxFlvH50L2nV3xdq3q2YvOWCZk_Y4zF25EdF5n32IKan7OHp-HX8Gbv5vqJ9WsD4rPDocIxJOc15VE_kP0pBbOQ-dXgAGZsJ8JCIwnl2W7nEE22SE5LAEK_CsBz_1OSLxOfovNYDveyn6lV-QkREabjyz9nZ7PPPk3k1UitUgCvcujKNUTiw9Eq4AVl7MwXdGRmkitp3wXoTQ2-N6DtFhH9WASbdmM32HhRmeEK-YHtpSPEV4x5sX2eMGA3KAARpPKHeq9CZzpp6wj5txtnBiDtO9BdLh_kHacRtNDJh77ctfxesjXvaHJOqttcJHTufQJtxo824f9nMhH1ARbtLWOT-tL0Y3OXKYQ7xxQlJbF4kzcYOHE45Glqf4nD9xxGLV2uatpYT9rLYxVYezGApBsfedsdidgTevZIWvzKst1bC2ka9_h9P-IY9mlL8QTCz-i3bW6-u4zuMntbhIE-Uv-TgGn4 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+Factors+for+Complete+Response+and+Recurrence+after+Transarterial+Chemoembolization+in+Hepatocellular+Carcinoma&rft.jtitle=Gut+and+liver&rft.au=Jeong%2C+Shin+Ok&rft.au=Kim%2C+Eui+Bae&rft.au=Jeong%2C+Soung+Won&rft.au=Jang%2C+Jae+Young&rft.date=2017-05-15&rft.issn=2005-1212&rft.eissn=2005-1212&rft.volume=11&rft.issue=3&rft.spage=409&rft_id=info:doi/10.5009%2Fgnl16001&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-2283&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-2283&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-2283&client=summon |